Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alector, Inc. (NASDAQ: ALEC) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the U.S. Securities and Exchange Commission’s EDGAR system. Alector is a late-stage clinical biotechnology company focused on neurodegenerative diseases, and its filings offer detailed insight into clinical progress, financial performance, and corporate actions.
Investors can review Alector’s Form 8-K filings for material events such as quarterly financial results, restructuring plans, and leadership changes. For example, 8-K reports describe the announcement of second and third quarter financial results, the Phase 3 INFRONT-3 trial outcome for latozinemab (AL001) in FTD-GRN and the associated reduction in workforce, and the appointment of Neil Berkley as Chief Financial Officer while he continues as Chief Business Officer. These filings also outline estimated restructuring charges and separation arrangements for departing executives.
Beyond current reports, users can access periodic filings such as Forms 10-K and 10-Q (when available) to examine Alector’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and investment balances. For a company developing late-stage and preclinical programs in neurodegeneration, these documents are key to understanding funding runway, partnering structures, and portfolio priorities.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly grasp the implications of complex disclosures. The platform also makes it easier to track insider transaction reports on Form 4 and other ownership-related filings, so users can monitor how executives and major holders interact with ALEC shares. Use this page to navigate Alector’s regulatory history, from clinical trial updates to financial and governance events, with AI tools that streamline document review.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of 6,908,054 shares of Alector Inc. common stock, representing 6.32% of the class as of 12/31/2025. Vanguard reports shared voting power over 605,402 shares and shared dispositive power over 6,908,054 shares, with no sole voting or dispositive power.
Vanguard states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Alector. It also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions are expected to report beneficial ownership separately.
BlackRock, Inc. filed an amended Schedule 13G reporting its passive ownership in Alector, Inc. common stock as of December 31, 2025. BlackRock reports beneficial ownership of 5,179,805 Alector shares, representing 4.7% of the outstanding common stock. It has sole power to vote 5,092,782 shares and sole power to dispose of 5,179,805 shares, with no shared voting or dispositive power.
The filing aggregates holdings of certain BlackRock business units and excludes other disaggregated units. BlackRock states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Alector. The filing also notes that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Alector’s outstanding common shares.
Alector, Inc. has appointed Neil Berkley as its Chief Financial Officer, effective December 10, 2025. He had been serving as Interim Chief Financial Officer since June 2025.
Mr. Berkley will continue in his role as Chief Business Officer and remains Alector’s principal financial officer. The company reports that there are no changes to his existing compensatory arrangements in connection with this appointment. Alector issued a press release about the appointment on December 12, 2025, which is included as Exhibit 99.1.
Alector, Inc. principal accounting officer Grace Wong-Sarad reported selling 4,753 shares of Alector common stock on 12/05/2025 at a price of $1.21 per share. The transaction was made under a Rule 10b5-1 trading plan adopted by her on 09/05/2025.
After this sale, she directly beneficially owns 122,982 shares of Alector common stock.
Alector (ALEC) reported an insider equity award. Principal Accounting Officer Grace Wong-Sarad filed a Form 4 for transactions on 11/10/2025.
The filing shows 32,343 restricted stock units acquired at $0. RSUs vest in 12 equal quarterly installments beginning on December 1, 2025. Following the award, beneficial ownership stands at 135,791 shares, held directly.
It also reports an employee stock option grant covering 48,535 shares at an exercise price of $1.31, expiring on 11/09/2035. Options vest in 48 equal monthly installments beginning on December 10, 2025.
Alector (ALEC) reported an insider equity award on Form 4. An officer (Chief Bus Ofcr & Interim CFO) acquired 65,000 restricted stock units on 11/10/2025 at $0, and was granted an employee stock option for 195,000 shares at an exercise price of $1.31, expiring 11/09/2035.
The RSUs vest in 12 equal quarterly installments beginning December 1, 2025. The option vests in 48 equal monthly installments beginning December 10, 2025. Following these awards, beneficial ownership was 411,570 shares, held directly.
Alector, Inc. (ALEC) reported insider equity awards to its Chief Executive Officer and Director. On 11/10/2025, the reporting person acquired 174,167 shares of Common Stock in the form of RSUs at $0. These RSUs vest in 12 equal quarterly installments beginning on December 1, 2025.
The reporting person was also granted an employee stock option to purchase 522,500 shares at an exercise price of $1.31 per share, vesting in 48 equal monthly installments beginning on December 10, 2025, and expiring on November 9, 2035. Following the reported transactions, the reporting person directly beneficially owned 2,524,387 shares. Additional shares are held indirectly through family trusts, as noted in the footnotes.
Alector (ALEC) filed its Q3 2025 10‑Q, reporting collaboration revenue of
The company announced topline Phase 3 INFRONT‑3 results: latozinemab did not meet the clinical co‑primary endpoint in FTD‑GRN; the open‑label extension and continuation study will be discontinued. On October 21, 2025, Alector committed to a 47% workforce reduction with expected restructuring charges of
Shares outstanding were 109,151,472 as of October 31, 2025. Year‑to‑date ATM sales delivered
Alector, Inc. furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company provided a press release detailing these results, attached as Exhibit 99.1.
The information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is furnished and not deemed “filed” under the Exchange Act. The filing also includes Exhibit 104 containing the cover page Inline XBRL tags.
Alector, Inc. (ALEC) announced a major restructuring tied to outcomes from its Phase 3 INFRONT-3 trial of latozinemab (AL001) in FTD-GRN. The company will reduce its workforce by approximately 49%, affecting about 75 employees, and will discontinue the open-label extension portion of INFRONT-3 as well as the continuation study for latozinemab.
Total incremental restructuring charges are expected to be about
Leadership update: Sara Kenkare-Mitra, Ph.D., President and Head of R&D, will resign effective
FAQ
What is the current stock price of Alector (ALEC)?
What is the market cap of Alector (ALEC)?
